Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • From the Analyst's Couch
  • Published:

New drug approvals for 2002

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1: New molecular entities approved by the FDA and EMEA from 1998–2002.

References

  1. Bolten, B. M. & DeGregorio, T. Trends in development cycles. Nature Rev. Drug Disc. 1, 335–336 (2002).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Supplementary information

Related links

Related links

FURTHER INFORMATION

US Food and Drug Administration

The European Agency for the Evaluation of Medicinal Products

Rights and permissions

Reprints and permissions

About this article

Cite this article

Frantz, S., Smith, A. New drug approvals for 2002. Nat Rev Drug Discov 2, 95–96 (2003). https://doi.org/10.1038/nrd1014

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd1014

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing